open access

Vol 85, No 7 (2014)
ARTICLES
Get Citation

Fetal hepatic artery flow assessment in prenatal diagnostics – a review of the literature

Michał Lipa, Robert B.B. Samaha, Dariusz Borowski, Mirosław Wielgoś, Piotr Węgrzyn
DOI: 10.17772/gp/1766
·
Ginekol Pol 2014;85(7).

open access

Vol 85, No 7 (2014)
ARTICLES

Abstract

Standards of screening tests for the most frequent fetal chromosomal defects in modern non-invasive prenatal diagnostics provide sensitivity of about 93-96%, with the false positive rate of 2.5%. During the first trimester scan, routinely performed between 11 and 13+6 week of pregnancy, the calculation of the risk for chromosomal aberrations is based on maternal age (MA), nuchal translucency (NT), levels of free β human chorionic gonadotropin (free β-hCG), pregnancy associated plasma protein A (PAPP-A) in maternal blood, as well as the parameters from extended ultrasound examination like evaluation of the nasal bone (NB), blood flow in ductus venosus (DV), visualization of the tricuspid valve with potential regurgitation (TR) or measurement of the frontomaxillary facial angle (FMFA). The 100% detection rate remains unachievable at present, despite constantly improving guidelines for specialists, quality of imaging, and advancement in ultrasound technology. Therefore, several studies have been undertaken to establish the group of ‘additional markers’ of chromosomal defects which, when combined with basic markers of routine screening tests, might increase the detection rate and approach it to 100%. Results of recent studies imply that evaluation of blood flow in fetal hepatic artery performed during the first trimester scan may become a new additional marker for chromosomal defects.

Abstract

Standards of screening tests for the most frequent fetal chromosomal defects in modern non-invasive prenatal diagnostics provide sensitivity of about 93-96%, with the false positive rate of 2.5%. During the first trimester scan, routinely performed between 11 and 13+6 week of pregnancy, the calculation of the risk for chromosomal aberrations is based on maternal age (MA), nuchal translucency (NT), levels of free β human chorionic gonadotropin (free β-hCG), pregnancy associated plasma protein A (PAPP-A) in maternal blood, as well as the parameters from extended ultrasound examination like evaluation of the nasal bone (NB), blood flow in ductus venosus (DV), visualization of the tricuspid valve with potential regurgitation (TR) or measurement of the frontomaxillary facial angle (FMFA). The 100% detection rate remains unachievable at present, despite constantly improving guidelines for specialists, quality of imaging, and advancement in ultrasound technology. Therefore, several studies have been undertaken to establish the group of ‘additional markers’ of chromosomal defects which, when combined with basic markers of routine screening tests, might increase the detection rate and approach it to 100%. Results of recent studies imply that evaluation of blood flow in fetal hepatic artery performed during the first trimester scan may become a new additional marker for chromosomal defects.
Get Citation

Keywords

Hepatic Artery, chromosomal aberrations, Trisomy 21, prenatal diagnostics

About this article
Title

Fetal hepatic artery flow assessment in prenatal diagnostics – a review of the literature

Journal

Ginekologia Polska

Issue

Vol 85, No 7 (2014)

DOI

10.17772/gp/1766

Bibliographic record

Ginekol Pol 2014;85(7).

Keywords

Hepatic Artery
chromosomal aberrations
Trisomy 21
prenatal diagnostics

Authors

Michał Lipa
Robert B.B. Samaha
Dariusz Borowski
Mirosław Wielgoś
Piotr Węgrzyn

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl